Ivan Horak, MD, on Early Clinical Efficacy of Allogeneic CD30.CAR EBVST Cell Therapy in Lymphomas

"Preliminary activity is very encouraging. These are heavily pretreated patients with Hodgkin lymphoma. In 14 patients from which data were presented there's 6 complete remissions and 6 partial remissions. So, the overall response rate is very encouraging and you have to consider that it’s a very low dose, under 40 million cells...In general, with detection of the cells, cell expansion is very rapid and very short, and doesn't really reachthe levels we see with autologous cells.”

REFERENCES

1. Quach D, Ramos C, Ganesh H, et al. CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana. Poster #167
2. Ahmed S, Flinn I, Mei M, et al. Updated results and correlative analysis: Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT trial). Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana. Poster #3338